Field Trip will focus on Treatment-Resistant Depression and Postpartum Depression as indications for drug development of FT-104.
Psychedelics
Wesana Health Announces Closing of PsyTech Acquisition
Wesana Health closes on its acquisition of PsyTech, solidifying its business model as it seeks a U.S. listing.
Psyched Wellness Commences Neurobehavioral Preclinical Trial Study on AME-1
Psyched Wellness moves a step closer to commencing its Phase I clinical trial on AME-1. The company is still targeting commercialization for 2022.
The Economics of Psychedelics
Roughly 8 million people per year are dying preventable deaths because of lack of (legal) access to psychedelic medicine. It's also killing the economy.
Mydecine Innovations Group Announces MYCO-001 Seamless Phase 2/3 Smoking Cessation Clinical Trial
Mydecine and Johns Hopkins plan a "seamless" (combined) Phase II/III clinical trial of MYCO-001 to treat nicotine addiction.
Red Light Holland Closes Majority Stake in Acadian Exotic Mushrooms, Partnering with Leading Canadian Fresh and Dried Mushroom Producers on East Coast Facility
Red Light Holland closes on its majority ownership in Acadian Exotic Mushrooms, now holding a 51% interest.
Oregon Psilocybin Panel Teams Up With Harvard To Research Psychedelic History And Impacts Of Reform
An Oregon state panel charged with advising on the implementation of a legal psilocybin therapy program has cleared a team of researchers to produce a comprehensive report on the science, history and culture of the psychedelic as regulators prepare to license facilities to administer it.
Washington Officials Join Cancer Patients In Federal Court Argument Pushing DEA To Allow Psilocybin Access
The Washington State attorney general’s office appeared alongside lawyers representing cancer patients on Thursday, telling a federal appeals panel that people in end-of-life care deserve legal access to psilocybin under state and federal right-to-try laws.
The DEA Proves It Must Be Immediately Abolished
The DEA fights to keep psychedelic drugs illegal while it admits these drugs have valuable medical uses. Meanwhile, Americans are dying every day from lack of legal access.
MINDCURE Announces Financial Results for Fiscal 2021
MINDCURE reports a net loss for the fiscal year of CAD$10.2 million as it prepares to deploy its iSTRYM digital therapeutics platform. Cash and equivalents of CAD$18.3 million.
Seattle Should Decriminalize All Drugs, City Task Force On Overdose Crisis Recommends
In response to the Seattle City Council’s request for policy advice on how to curb overdose deaths, a local task force is recommending the widespread decriminalization of all drugs.
Kelsey Ramsden on MINDCURE iSTRYM Beta and Commercial Distribution
After our July interview with CEO Kelsey Ramsden about the company’s Ibogaine synthesis, August brought more exciting announcements for Mind Cure Health Inc.
Red Light Closes Acquisition of Mera Life Sciences and Files Quarterly Financial Statements
Red Light Holland reports its Q1 for fiscal year 2022. The company also confirms closing on its acquisition of Mera Life Sciences.
Denver Psychedelics Activists Push To Expand Psilocybin Decriminalization To Allow Gifting And Communal Use
Denver activists who successfully led a 2019 campaign to make the city the first in the U.S. to decriminalize psilocybin possession have their eyes set on broader reform, with plans in the works to end the criminalization of noncommercial gifting and communal use of the psychedelic.
Psilocybin appears to alter how the brain integrates tactile sensory inputs
A new double-blind, placebo-controlled neuroimaging study sheds light on how psilocybin alters the way in which the brain processes tactile sensations and mental representations of one’s body.